Piramal Pharma · NSE: PPLPHARMA · BSE: 543635
Q1 FY27 results · Apr–Jun 2026
Piramal Pharma reported revenue from operations of ₹2,269.92 crore (up 17.4% from Q1 FY26) and net loss of ₹69.39 crore for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,269.92 | 1,933.71 | +17.4% | 2,751.77 | −17.5% |
| Other income | 89.41 | 58.40 | +53.1% | 46.06 | +94.1% |
| Total income | 2,359.33 | 1,992.11 | +18.4% | 2,797.83 | −15.7% |
| Profit before share of associates & JVs and tax | (27.02) | (97.59) | Loss narrowed | 29.43 | Turned loss |
| Share of profit/(loss) of associates & JVs | 19.56 | 18.57 | 13.58 | ||
| Net profit for the period | (69.39) | (81.70) | Loss narrowed | (8.82) | Loss widened |
| EPS, basic (₹) | (0.52) | (0.62) | Loss narrowed | (0.07) | Loss widened |
| Net margin (%) | -3.1 | -4.2 | -0.3 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,124.95 | 969.88 | +16.0% | 1,489.06 | −24.5% |
| Other income | 114.63 | 180.92 | −36.6% | 183.69 | −37.6% |
| Total income | 1,239.58 | 1,150.80 | +7.7% | 1,672.75 | −25.9% |
| Profit before tax | 149.48 | 142.58 | +4.8% | 331.85 | −55.0% |
| Net profit for the period | 113.48 | 113.14 | +0.3% | 261.63 | −56.6% |
| EPS, basic (₹) | 0.85 | 0.85 | +0.0% | 1.97 | −56.9% |
| Net margin (%) | 10.1 | 11.7 | 17.6 |
Consolidated
- Filed with BSE
- 29 Jul 2026, 20:55 IST
- Board meeting
- 29 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Jul 2026, 20:55 IST
- Board meeting
- 29 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE